About This Fund
The LSP Health Economics Fund is a 2012-vintage venture capital fund managed by Life Sciences Partners (LSP), now operating as EQT Life Sciences following LSP's integration into EQT Group in 2022. With approximately €112 million in capital commitments, this fund represents LSP's inaugural dedicated health economics investment vehicle, established to back healthcare innovations that simultaneously deliver clinical benefit and reduce the cost of care for payers and health systems. Based in Amsterdam, Netherlands, LSP brought over 20 years of European life sciences investment experience to this strategy at its launch, having operated since the early 1990s as one of the continent's most active and experienced healthcare venture managers.
The LSP Health Economics Fund targets late-stage and early-commercialization companies developing medical devices, diagnostics, and digital health technologies across Europe and North America. The fund's core investment thesis centers on companies whose products can demonstrate measurable health economic value — improving patient outcomes while reducing total healthcare system costs — a value proposition increasingly required by reimbursement bodies, hospital procurement committees, and national health technology assessment agencies. Portfolio companies typically have de-risked technology platforms and are preparing for or already in early commercial deployment, positioning the fund at the late venture to early growth stage boundary.
LSP's Health Economics strategy demonstrated sustained institutional validation across multiple fund generations: the original fund (€112 million, 2012) was followed by LSP Health Economics Fund 2 (€280 million, 2018 vintage), reflecting more than a doubling of fund size in seven years. Portfolio highlights across the strategy include Neuravi (stroke thrombectomy device, acquired by Johnson & Johnson), Endotronix (heart failure remote monitoring, acquired by Edwards Lifesciences in 2024), and Onera Health (sleep diagnostics). EQT Life Sciences has invested in more than 25 companies through this strategy over a decade, with the original LSP Health Economics Fund serving as the foundation for one of Europe's most respected medtech and digital health venture franchises.